Biotechnology
VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled
SHANGHAI, March 31, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully completed its recruiting target of 150 subjects for the Phase-III registration clinical trial inChina to evalu...
2021-03-31 23:53
1569
Five New 'Key Opinion Leaders' Appointed to Blinkcns Scientific Advisory Board
Dr. Angelo Antonini, Dr. Matteo Bologna, Roy Jones, Dr. Fidias Leon-Sarmiento, and Dr.Fabrizio Stocchi, will help guide company as they advance central nervous system research CHARLESTON, South Carolina, March 31, 2021 /PRNewswire/ -- Blinkcns, Inc, a biotechnology company pioneering blink refle...
2021-03-31 21:00
753
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-03-31 20:45
3115
BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T
VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request ...
2021-03-31 20:00
2354
Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)
* BLA submission to the U.S. FDA follows successful conclusion of Evive's Global Phase III Clinical Trial for chemotherapy-induced neutropenia in breast cancer patients. * Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a complet...
2021-03-31 11:26
2170
Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...
2021-03-31 10:00
4450
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...
2021-03-31 09:00
1957
Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma
SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-31 08:00
3570
Viva Biotech Announced 2020 Annual Results
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...
2021-03-31 07:03
3165
European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer
mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughoutEurope. MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the Eur...
2021-03-31 05:30
10213
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing
WETTEREN, Belgium, March 31, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufact...
2021-03-31 01:04
1323
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
2021-03-30 21:10
2702
Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-30 20:52
3422
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
1599
TurtleTree Scientific and JSBiosciences enter into a strategic partnership for the development of cell culture media and contract manufacturing services
SINGAPORE, March 29, 2021 /PRNewswire/ -- JSBiosciences (hereinafter referred to as "JSBio") has just announced a partnership with TurtleTree Scientific (hereinafter referred to as "TTS"). Both parties have signed a letter of intent to collaborate in the development of cell culture media at a com...
2021-03-30 06:00
1557
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...
2021-03-30 04:30
4240
GenScript Biotech Reports Full Year 2020 Financial Results
NANJING, China, Mar. 30, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK) today held its 2020 Annual Results Conference, announcing its business updates and financial performance. The Group earned a USD 390 million revenue, representing a 42.9% YoY growth, and aUSD 260 million ...
2021-03-30 03:19
5003
Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
CINCINNATI, March 30, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...
2021-03-30 02:55
1209
GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
* Reported a revenue of approximately USD 390 million, a 42.9% YoY increase, and a gross profit ofUSD 260 million, achieving YoY growth of 41.9%. * The Group's non-cell therapy business witnessed its fastest growth in five years with a net profit increase of more than 100%; while its cell ther...
2021-03-30 01:35
3935
Tigermed Reports 2020 Annual Results With Solid Growth
HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...
2021-03-29 21:21
3944
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9172
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
2024-04-18 21:26
8839
Animated Life in Yunnan
2024-04-18 14:00
7829
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7751